mean LVEF = 23 ± 8%; NYHA class: I = 13%, II = 63%, III = 24%; CAD >70% = 11% CAT trial N=104 patients with symptomatic Inclusion criteria: symptomatic N=50 N=54 Primary DCM for ≤9 months, LVEF ≤30%, DCM and LVEF ≤30% endpoint: Patients assigned to ICD Treatment not described NYHA class II or III, age Intervention group: therapy underwent All-cause mortality years, the absence of CAD Bänsch et al. implantation of a at 1 year (2002) age = 52 ± 10 years; Exclusion criteria: patients with transvenous defibrillator Secondary CAD, a history of prior MI, system, under general gender = 86% male; endpoint: myocarditis, excessive alcohol anaesthesia. A Germany median duration of symptoms = consumption, a history of defibrillation threshold of All-cause mortality 3.0 years; symptomatic bradycardia, VT and <20 J was mandatory. All at 2 and 6 years VF, listed for heart transplantation devices were capable of sinus rhythm = 80%; Cardiac transplant NHMRC Level II at the time of presentation, storing episode data and at 1 year LBBB = 85%; significant valvular disease, and electrograms. A VT zone with a detection rate of hypertrophic or restricted CM Survival of cardiac RBBB = 8%; SIGN RCT: 200 bpm was arrest Median follow-up: 5.5 ± Adequate quality mean LVEF = 24 ± 6%; programmed in all 2.2 years Cardiac death at with a moderate patients. All shocks were NYHA class: II = 67%, III = 1 year risk of bias programmed to a 33%; maximum output of 30 J. Sustained VT inducible VT = 6%; The pacemaker rate was Sustained VA programmed to 40 bpm. inducible VF = 16% requiring treatment Control group: SCD at 1 year age = 52 ± 12 years; gender = 74% male; median duration of symptoms =
mean LVEF = 23 ± 8%; NYHA class: I = 13%, II = 63%, III = 24%; CAD >70% = 11% CAT trial Bänsch et al. (2002) Germany NHMRC Level II SIGN RCT: Adequate quality with a moderate risk of bias N=104 patients with symptomatic DCM and LVEF ≤30% Intervention group: age = 52 ± 10 years; gender = 86% male; median duration of symptoms = 3.0 years; sinus rhythm = 80%; LBBB = 85%; RBBB = 8%; mean LVEF = 24 ± 6%; NYHA class: II = 67%, III = 33%; inducible VT = 6%; inducible VF = 16% Control group: age = 52 ± 12 years; gender = 74% male; median duration of symptoms = Inclusion criteria: symptomatic DCM for ≤9 months, LVEF ≤30%, NYHA class II or III, age years, the absence of CAD Exclusion criteria: patients with CAD, a history of prior MI, myocarditis, excessive alcohol consumption, a history of symptomatic bradycardia, VT and VF, listed for heart transplantation at the time of presentation, significant valvular disease, and hypertrophic or restricted CM Median follow-up: 5.5 ± 2.2 years N=50 Patients assigned to ICD therapy underwent implantation of a transvenous defibrillator system, under general anaesthesia. A defibrillation threshold of <20 J was mandatory. All devices were capable of storing episode data and electrograms. A VT zone with a detection rate of 200 bpm was programmed in all patients. All shocks were programmed to a maximum output of 30 J. The pacemaker rate was programmed to 40 bpm. N=54 Treatment not described Primary endpoint: All-cause mortality at 1 year Secondary endpoint: All-cause mortality at 2 and 6 years Cardiac transplant at 1 year Survival of cardiac arrest Cardiac death at 1 year Sustained VT Sustained VA requiring treatment SCD at 1 year
1393-CMRforDCM.docx